The President & CEO of Sophiris Bio (SPHS) is Buying Shares


Today, the President & CEO of Sophiris Bio (NASDAQ: SPHS), Randall Woods, bought shares of SPHS for $26.3K.

This recent transaction increases Randall Woods’ holding in the company by 100% to a total of $26.8K. This is Woods’ first transaction since reporting a Sell transaction on ARNA back in April 2015

See today’s analyst top recommended stocks >>

Currently, Sophiris Bio has an average volume of 177.8K.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $8.33, reflecting a 207.4% upside. Starting in October 2017, SPHS received 22 Buy ratings in a row. Three different firms, including Maxim Group and Piper Jaffray, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.

Read More on SPHS:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts